Portal de Periódicos da CAPES

Long-lasting severe immune dysfunction in Ebola virus disease survivors

2020; Nature Portfolio; Volume: 11; Issue: 1 Linguagem: Inglês

10.1038/s41467-020-17489-7

2041-1723

Aurélie Wiedemann, Emile Foucat, Hakim Hocini, Cécile Lefebvre, Boris P. Hejblum, Mélany Durand, Miriam Krüger, Alpha Kabinet Keïta, Ahidjo Ayouba, Stéphane Mély, José-Carlos Fernandez, Abdoulaye Touré, Slim Fourati, Claire Lévy‐Marchal, Hervé Raoul, Éric Delaporte, Lamine Koivogui, Rodolphe Thiébaut, Christine Lacabaratz, Yves Lévy, Ahidjo Ayouba, Eric Delaporte, Alpha Kabinet Keïta, Lamine Koivogui, Christine Lacabaratz, Laura March, Yves Lévy, Hervé Raoul, Abdoulaye Touré,

SARS-CoV-2 and COVID-19 Research

Long-term follow up studies from Ebola virus disease (EVD) survivors (EBOV_S) are lacking. Here, we evaluate immune and gene expression profiles in 35 Guinean EBOV_S from the last West African outbreak, a median of 23 months (IQR [18-25]) after discharge from treatment center. Compared with healthy donors, EBOV_S exhibit increases of blood markers of inflammation, intestinal tissue damage, T cell and B cell activation and a depletion of circulating dendritic cells. All survivors have EBOV-specific IgG antibodies and robust and polyfunctional EBOV-specific memory T-cell responses. Deep sequencing of the genes expressed in blood reveals an enrichment in 'inflammation' and 'antiviral' pathways. Integrated analyses identify specific immune markers associated with the persistence of clinical symptoms. This study identifies a set of biological and genetic markers that could be used to define a signature of "chronic Ebola virus disease (CEVD)".